Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

This article was originally published here

The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments. Both

The post Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply